Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter Non-interventional Study of Osimertinib Administration in Patients With NSCLC Progression Occurred During or After Therapy With EGFR Tyrosine Kinase Inhibitors, With Confirmed Т790М Positive Mutation in EGFR Gene

NCT05314296 is registered in ClinicalTrials.gov with N.N. Blokhin National Medical Research Center of Oncology as lead sponsor.

NCT NCT05314296
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05314296 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter Non-interventional Study of Osimertinib Administration in Patients With NSCLC Progression Occurred During or After Therapy With EGFR Tyrosine Kinase Inhibitors, With Confirmed Т790М Positive Mutation in EGFR Gene
Lead sponsor
N.N. Blokhin National Medical Research Center of Oncology
Phase
Observational
Overall status
Unknown status
Start date
June 1, 2020
Completion date
December 31, 2022
Enrollment
70 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

egfr gene mutation, non small cell lung cancer, t790m